Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators

Abstract Background Severe immune-related Adverse Events (irAEs) develop in 10–27% of patients treated with Immune-Oncology (IO) [Powles (Lancet 391:748–757, 2018); Galsky (Lancet 395:1547–1557, 2020); Haanen (Ann Oncol 28:119–142, 2017)]. The aim of our study was to evaluate efficacy and clinical o...

Full description

Bibliographic Details
Main Authors: Marco Stellato, Giuseppe Procopio, Ugo De Giorgi, Marco Maruzzo, Davide Bimbatti, Alessia Mennitto, Andrea Sbrana, Giandomenico Roviello, Chiara Casadei, Pierangela Sepe, Sandro Pignata, Daniele Santini
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Journal of Translational Medicine
Subjects:
Renal cell carcinoma
Immunotherapy
Immune-related adverse events
Online Access:https://doi.org/10.1186/s12967-021-03008-9

Internet

https://doi.org/10.1186/s12967-021-03008-9

Similar Items